by Elena Iemma | Jan 12, 2026 | Blog, News
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | Dec 23, 2025 | Blog
EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic At EpiVax, we believe in the power of science to improve human health, but we also recognize that science alone cannot reach every community. That...
by Elena Iemma | Dec 1, 2025 | Blog
Doing Well and Giving Back in December On Being Human Humans share 96-98% of our DNA with non-human primates. And yet, for many years, we have caged our “NHP” brothers and sisters and used them to validate our scientific hypotheses. Finally,...
by Elena Iemma | Oct 22, 2025 | Blog
The Power of Tregs: From Sakaguchi’s Nobel Discovery to EpiVax Innovation If you know us, you know we love Tregs. Regulatory T cells (Tregs) are central to how we think about the immune system and nearly everything we do at EpiVax. So, we were thrilled to see this...
by Elena Iemma | Aug 19, 2025 | Blog
The Tregs as Medicine Symposium September 26, 2025 | The Westin Hotel, Meguro Tokyo The Tregs as Medicine: Tolerance and InTolerance Symposium will bring together leading scientists and clinicians to examine how regulatory T cells (Tregs) and tolerance...
by Elena Iemma | Jul 29, 2025 | Blog
Optimize Your Immunogenicity Strategy with Trusted Expert Advice Immunogenicity is a critical factor in biologic drug development, with the potential to determine a therapy’s success or failure. Undesirable immune responses, including the formation of anti-drug...
